netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Paclitaxel found 17 matches

Formulary items 5 matches
   
Open monograph to display formulary status BNF Category
  Cytotoxic Drug Paclitaxel Malignant disease and immunosuppression - Taxanes - 08.01.05
  Cytotoxic Drug Paclitaxel - Albumin Bound Formulation  (Abraxane®) Malignant disease and immunosuppression - Taxanes - 08.01.05
  Cytotoxic Drug Atezolizumab Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
  Cytotoxic Drug Gemcitabine Malignant disease and immunosuppression - Antimetabolites - 08.01.03
  Cytotoxic Drug Pembrolizumab  (Keytruda®) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section MHRA Drug Safety Update (Jan 2022): Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error (08.01.05)
link in drug section MHRA Drug Safety Update (Jan 2022): Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error (08.01.05)
link in drug section NICE TA284:Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (08.01.05)
link in drug section NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (08.01.05)
link in drug section NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (08.01.05)
link in drug section NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (08.01.05)
link in drug section NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (08.01.02)
link in drug section NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (08.01.03)
link in drug section NICE TA476 Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (08.01.05)
link in drug section NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer (08.01.05)
link in drug section NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (08.01.05)
link in drug section NICE TA770: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (08.01.05)


 

netFormulary